Advancing Computational Toxicology to Better Predict Safety Outcomes

  • Landscape of in silico models for small molecules and larger molecules where limited clinical and preclinical datasets hinder model accuracy and validation
  • New data integration and modelling approaches with knowledge graph and generative models for connecting heterogenous datasets and modelling animal variabilities
  • Explore how to evaluate combination therapy safety by modelling target pathway interactions dose considerations and additive or offsetting toxicity risks to support more confident regulatory acceptance